Alpine Global Management’s United Therapeutics UTHR Stock Holding History

Alpine Global Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,389	Closed	-$475K	–	430
2019 Q4	$475K	Buy	+5,389	New	+$474K	0.1%	167
2016 Q3	–	Sell	-2,467	Closed	-$261K	–	157
2016 Q2	$261K	Buy	+2,467	New	+$275K	0.12%	81
2016 Q1	–	Sell	-3,966	Closed	-$621K	–	198
2015 Q4	$621K	Buy	+3,966	New	+$577K	0.2%	66

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Alpine Global Management's UTHR Position: Q1 2020 in Review

Alpine Global Management sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 5,389 shares — an estimated $475K sold.

Alpine Global Management first reported a position in UTHR in Q4 2015 and held it in 3 quarters. The position peaked at $621K in Q4 2015. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

Alpine Global Management reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
Alpine Global Management sold 5,389 United Therapeutics shares in Q1 2020, an estimated $475K.
Alpine Global Management first reported a position in United Therapeutics in Q4 2015 and held it in 3 quarters.
Alpine Global Management's United Therapeutics position peaked at $621K in Q4 2015.
303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.